Economies’ policy trajectories have a significant impact on biopharmaceutical investment decisions, perhaps more than costs and market size, according to local executives. Our new study, Measuring the Global Biomedical Pulse: The Biopharmaceutical Investment & Competitiveness (BCI) Survey, finds that economies with policy environments that support investment and innovation rank as the most attractive for biopharmaceutical investment in the eyes of top level executives operating on the ground. The study, commissioned by PhRMA, also finds that notwithstanding low costs and considerable market potential, the BRIC economies plus Turkey still fall into the bottom group of markets sampled in the study.
The BCI polls local managing directors and high level executives of multinational biopharmaceutical companies in 15 economies as to how different aspects of the local policy environment impact their ability to allocate investments to these markets. By gauging the on-the-ground “pulse” of a given market and translating it into a quantitative score, the BCI enables a unique and highly relevant snapshot of economies’ biomedical competitiveness.
Full report & Executive Summary: Measuring the Biomedical Pulse: The BCI Survey – 2015Share